FIELD: medicine.
SUBSTANCE: invention can be used for reduction of MARCKS-related release of, at least, one inflammation mediator from, at least, one inflammation cell, contained in granule inside said cell. For this purpose into said cell introduced is efficient inhibiting degranulation amount of composition, which contains mixture of two or more myristoylated N-terminal peptides. Efficient amount of composition reduces inflammation mediator release from inflammation cell from 5 to 99% in comparison with said inflammation mediator release in absence of composition.
EFFECT: invention makes it possible simultaneously to reduce inflammation and block secretion of mucus during inflammation, eliminating at the same time impact on other mechanisms of inflammation process.
9 cl, 15 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF DEPRESSING INFLAMMATION MEDIATOR RELEASE AND PEPTIDES APPLIED FOR THIS PURPOSE | 2007 |
|
RU2423376C2 |
| METASTASIS INHIBITORS | 2014 |
|
RU2681213C2 |
| MUCIN HYPERSECRETION INHIBITORS AND METHODS OF APPLICATION THEREOF | 2006 |
|
RU2423379C2 |
| PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATORY CYTOKINES | 2019 |
|
RU2816868C2 |
| ANTIBACTERIAL PEPTIDES | 2007 |
|
RU2468033C2 |
| IMPROVED METHODS AND COMPOSITIONS FOR WOUND HEALING | 2007 |
|
RU2542471C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING APL TYPE PEPTIDE | 2018 |
|
RU2778402C2 |
| PRODUCT AND METHOD FOR MUCUS VISCOSITY NORMALIZATION | 2014 |
|
RU2750211C2 |
| COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF DISEASES, CONDITIONS, OR PROCESSES CHARACTERIZED BY ABERRANT FIBROBLAST PROLIFERATION AND EXTRACELLULAR MATRIX DEPOSITION | 2012 |
|
RU2620066C2 |
| APPLICATION OF HEPARIN-BINDING ANTAGONISTS IN INHIBITING BRADYKININ RELEASING | 2000 |
|
RU2251433C2 |
